Dimensional Fund Advisors LP Acquires 28,074 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Dimensional Fund Advisors LP increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 283.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 37,981 shares of the company's stock after acquiring an additional 28,074 shares during the period. Dimensional Fund Advisors LP owned approximately 0.08% of Tyra Biosciences worth $528,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Tyra Biosciences during the 4th quarter valued at approximately $149,000. Rhumbline Advisers lifted its holdings in Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after acquiring an additional 1,027 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Tyra Biosciences by 5.2% during the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company's stock valued at $626,000 after purchasing an additional 2,221 shares during the period. US Bancorp DE bought a new position in Tyra Biosciences during the 4th quarter worth $50,000. Finally, Alta Partners Management Company L.P. acquired a new stake in Tyra Biosciences in the fourth quarter worth $56,716,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TYRA shares. Wedbush reissued an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Friday, March 28th. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Monday, March 31st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences currently has a consensus rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Trading Up 3.1%

TYRA traded up $0.30 on Tuesday, reaching $9.98. The company had a trading volume of 252,076 shares, compared to its average volume of 261,733. The company has a fifty day moving average of $9.53 and a 200-day moving average of $12.76. The company has a market capitalization of $529.84 million, a P/E ratio of -6.20 and a beta of 1.17. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Research analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.